Drug Trial Radar · NCT04552600
Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy.
Last checked: Nov 19, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Sep 1, 2019
Primary completion
Aug 10, 2022
Study completion Aug 10, 2022
Sponsor
- Lead sponsor
- Natureceuticals Sdn BhdIndustry
- Sponsor type
- Industry
- Collaborators
- Ministry of Agriculture, Malaysia; Quest International University, Malaysia.; Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia; Universiti Sains Malaysia
- First posted
- Sep 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Diabetic retinopathy (DR) is a common complication of diabetes mellitus that leads to loss of vision and blindness among working age adults. An ideal adjunctive agent for treating DR hence should be polymorphic and possess antiangiogenic, neuroprotective, anti-inflammatory, anti-oxidant as well as anti-ischaemic properties.Natureceuticals Sdn Bhd assessed the efficacy of core ingredient of Nuvastatic™, Lanctos 75™ for the treatment and management of the diabetic retinopathic condition.
Conditions
- Diabetic Retinopathy
Interventions
NuvastaticDrug
Phase 1b Interventional, multi-centered, double-masked, randomized
PlaceboOther
Phase 1b Interventional, multi-centered, double-masked, randomized
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate efficacy of Nuvastatic - Retinal ThicknessTime frame: 12 months
- To evaluate efficacy of Nuvastatic - protein biomarkersTime frame: 12 months
- To evaluate safety of Nuvastatic - Letter ScoreTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fifepoint Multispeciality Hospital Pvt. Ltd.
Pune, Maharashtra, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.